Literature DB >> 11266439

The pro domain of beta-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain.

X P Shi1, E Chen, K C Yin, S Na, V M Garsky, M T Lai, Y M Li, M Platchek, R B Register, M K Sardana, M J Tang, J Thiebeau, T Wood, J A Shafer, S J Gardell.   

Abstract

beta-Secretase (BACE) is a membrane-bound aspartyl protease that cleaves the amyloid precursor protein to generate the N terminus of the amyloid beta peptide. BACE is expressed as a precursor protein containing Pre, Pro, protease, transmembrane, and cytosolic domains. A soluble BACE derivative (PreProBACE460) that is truncated between the protease and transmembrane domains was produced by baculovirus-mediated expression. ProBACE460 was purified from conditioned media of infected insect cells using immobilized concanavalin A and immobilized BACE inhibitor, P10-P4' Stat(Val). Furin cleaves ProBACE460 between the Pro and protease regions to generate mature BACE460. The k(cat)/K(m) of ProBACE460 when assayed with a polypeptide substrate is only 2.3-fold less than that of BACE460. This finding and the similar inhibitory potency of P10-P4' Stat(Val) for ProBACE460 and BACE460 suggest that the Pro domain has little effect on the BACE active site. Exposure of ProBACE460 to guanidine denaturation/renaturation results in a 7-fold higher recovery of BACE activity than when BACE460 is similarly treated. The presence of free BACE Pro peptide during renaturation of BACE460 but not ProBACE460 increases recovery of activity. These findings show that the Pro domain in ProBACE460 does not suppress activity as in a strict zymogen but does appear to facilitate proper folding of an active protease domain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11266439     DOI: 10.1074/jbc.m009200200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

Review 1.  Spotlight on BACE: the secretases as targets for treatment in Alzheimer disease.

Authors:  C Dingwall
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 2.  Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease.

Authors:  Vivian Hook; Gregory Hook; Mark Kindy
Journal:  Biol Chem       Date:  2010-08       Impact factor: 3.915

Review 3.  Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

Authors:  Xiaoyang Luo; Riqiang Yan
Journal:  Int J Clin Exp Pathol       Date:  2010-07-08

Review 4.  The beta-secretase, BACE: a prime drug target for Alzheimer's disease.

Authors:  R Vassar
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

5.  Pharmacological applications of a novel neoepitope antibody to a modified amyloid precursor protein-derived beta-secretase product.

Authors:  Guoxin Wu; Sethu Sankaranarayanan; Donna L Montgomery; Adam J Simon; Zhiqiang An; Mary J Savage
Journal:  Protein Cell       Date:  2011-08-06       Impact factor: 14.870

6.  Natural Modulators of Amyloid-Beta Precursor Protein Processing.

Authors:  C Zhang; R E Tanzi
Journal:  Curr Alzheimer Res       Date:  2012-09-13       Impact factor: 3.498

7.  The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.

Authors:  Gregory Hook; Vivian Hook; Mark Kindy
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 8.  β-Secretase: its biology as a therapeutic target in diseases.

Authors:  Haibo Wang; Rena Li; Yong Shen
Journal:  Trends Pharmacol Sci       Date:  2013-02-27       Impact factor: 14.819

9.  Development of an Efficient Enzyme Production and Structure-Based Discovery Platform for BACE1 Inhibitors.

Authors:  Yu-Chen Yen; Annalissa M Kammeyer; Katherine C Jensen; Jagannadharao Tirlangi; Arun K Ghosh; Andrew D Mesecar
Journal:  Biochemistry       Date:  2019-10-22       Impact factor: 3.162

10.  Reduced amyloid deposition in mice overexpressing RTN3 is adversely affected by preformed dystrophic neurites.

Authors:  Qi Shi; Marguerite Prior; Wanxia He; Xiangying Tang; Xiangyou Hu; Riqiang Yan
Journal:  J Neurosci       Date:  2009-07-22       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.